Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3423761 | 1.00 | MAOB (0.47) | MAOBMAOASCN9AATML3MBTL1 | |
| SCHEMBL6027915 | 1.00 | MAOB (0.47) | MAOBMAOASCN9AATML3MBTL1 | |
| SCHEMBL8035957 | 0.78 | DRD2 (0.53) | — | |
| SCHEMBL3427290 | 0.78 | ATM (0.73) | MAOBATML3MBTL1 | |
| SCHEMBL3423999 | 0.78 | ATM (0.73) | MAOBATML3MBTL1 | |
| SCHEMBL3424000 | 0.78 | ATM (0.73) | MAOBATML3MBTL1 | |
| SCHEMBL3423796 | 0.77 | ATM (0.68) | MAOBMAOASCN9AATML3MBTL1 | |
| SCHEMBL3423798 | 0.77 | ATM (0.68) | MAOBMAOASCN9AATML3MBTL1 | |
| SCHEMBL3425487 | 0.77 | ATM (0.68) | MAOBMAOASCN9AATML3MBTL1 | |
| SCHEMBL5020048 | 0.70 | MAOB (0.61) | MAOBMAOASCN9APPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649005-B2 | (R)(4-Pentyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine; monoamine oxidase inhibitors; neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-19 | — | — | US | disclosed |
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | HTR7, MAOB, CYP2A7 | MAOB 2/4885MAOA 12/4885SCN9A 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.